{"result": "(\"entity\"<|>VITAMINA D<|>EVENT<|>A fat-soluble vitamin that may be insufficient in patients on prolonged parenteral nutrition, impacting their health.)\n##\n(\"entity\"<|>ESTEATOSIS HEPÁTICA<|>EVENT<|>A condition characterized by the accumulation of fat in the liver, commonly observed in patients after starting parenteral nutrition.)\n##\n(\"entity\"<|>COLESTASIS<|>EVENT<|>A condition where bile flow is reduced or blocked, often associated with parenteral nutrition and can occur after steatosis.)\n##\n(\"entity\"<|>CIRROSIS<|>EVENT<|>A late stage of scarring (fibrosis) of the liver caused by many forms of liver diseases and conditions, including prolonged parenteral nutrition.)\n##\n(\"entity\"<|>TRASPLANTE HEPÁTICO<|>EVENT<|>A surgical procedure to replace a diseased liver, which may be necessary for patients with advanced liver disease due to parenteral nutrition.)\n##\n(\"entity\"<|>ENFERMEDAD HEPÁTICA<|>EVENT<|>Liver disease that can be exacerbated by parenteral nutrition, affecting liver function and health.)\n##\n(\"entity\"<|>OLIGOELEMENTOS<|>EVENT<|>Trace elements that are essential for health, which may need to be managed carefully in patients receiving parenteral nutrition.)\n##\n(\"relationship\"<|>VITAMINA D<|>NUTRICIÓN PARENTERAL<|>Vitamin D levels may be insufficient in patients on prolonged parenteral nutrition, indicating a need for careful monitoring.<|>6)\n##\n(\"relationship\"<|>ESTEATOSIS HEPÁTICA<|>NUTRICIÓN PARENTERAL<|>Hepatic steatosis is a common complication that can occur within weeks of starting parenteral nutrition.<|>7)\n##\n(\"relationship\"<|>COLESTASIS<|>NUTRICIÓN PARENTERAL<|>Cholestasis is often associated with parenteral nutrition and typically occurs after the development of steatosis.<|>6)\n##\n(\"relationship\"<|>CIRROSIS<|>NUTRICIÓN PARENTERAL<|>Cirrhosis can develop as a severe complication in patients who have been on prolonged parenteral nutrition.<|>5)\n##\n(\"relationship\"<|>TRASPLANTE HEPÁTICO<|>CIRROSIS<|>Liver transplantation may be required for patients who develop cirrhosis due to complications from parenteral nutrition.<|>8)\n##\n(\"relationship\"<|>ENFERMEDAD HEPÁTICA<|>NUTRICIÓN PARENTERAL<|>Underlying liver disease can complicate the management of patients receiving parenteral nutrition.<|>7)\n##\n(\"relationship\"<|>OLIGOELEMENTOS<|>NUTRICIÓN PARENTERAL<|>Management of trace elements is crucial in patients receiving parenteral nutrition to prevent deficiencies and complications.<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: itamínicos de NP, se cu-\nbren los requerimientos diarios de vitaminas liposolu-\n\nbles e hidrosolubles, aunque se ha observado que el\naporte de vitamina D (200 UI), puede ser insuficiente\nen los pacientes con regímenes de NP prolongados48, 67.\n\n7.5. Complicaciones hepatobiliares (CHB)\n\nLa esteatosis hepática es común 1-4 semanas tras\nel comienzo de la NP, aunque inicialmente es rever-\nsible y fundamentalmente periportal. La esteatosis\npodría progresar a esteatohepatitis y cirrosis. La co-\nlestasis está también asociada a la NP, pero típica-\nmente ocurre después de la esteatosis. Si la afecta-\nción hepática progresa, podría evolucionar a una\ncirrosis y terminar en un trasplante hepático-intestinal.\n\nLa CHB en pacientes con NP es muy prevalente, ob-\nservándose una elevación transitoria de las enzimas\nhepáticas en las primeras semanas de la NP en el 40-\n70% de los pacientes, que suele ser reversible. En pa-\ncientes con regímenes de NP prolongados, se han ob-\nservado casos de hepatopatía avanzada en el 15-40%\nde los pacientes68.\n\nLa etiología de la CHB de los pacientes con NP es\nmultifactorial (figura 1).\n\n• Causas independientes de la NP:\n\n  - Drogas hepatotóxicas.\n  - Enfermedad hepática subyacente: hasta el 24%\n    de las CHB en pacientes con NP se podrían ex-\n    plicar por una enfermedad hepatobiliar de\n    base69.\n  - Enfermedad de base:\n\n    - Existen estudios que demuestran que la en-\n      fermedad hepática asociada a NP está relacio-\n      nada con la longitud del intestino delgado\n\nTabla 6. Manejo de oligoelementos en situaciones especiales48.\n\n| Oligoelemento | CRD | Enfermedad carencial | Consideraciones clínicas |\n|---------------|-----|----------------------|--------------------------|\n| Cromo | 0 | Muy raro | · No es necesario añadir a la NP, ya presente como contaminante |\n| Cobre | 0,3-0,05 mg | Sí | · Se excreta por bilis<br>· No administrar en insuficiencia hepática severa o colestasis.<br>· Incrementar aporte en DPCC |\n| Hierro | 0 | Sí | · Control metabolismo férrico en NP larga evolución<br>· Incompatible con emulsiones lipídicas |\n| Manganeso | 55 μg | No | · No administrar en insuficiencia hepática severa o colestasis |\n| Selenio | 60-100 μg | Sí | · Añadir si el preparado de oligoelementos no lo incluye<br>· Incrementar aporte en DPCC |\n| Zinc | 3-4 mg | Sí | · Aumento de requerimientos en quemados y pérdidas intestinales |\n\nCRD: cantidad diaria recomendada; DPCC: diálisis peritoneal continua cíclica.\n---\nTema 48. Nutrición parenteral 773\n\n| Etiología de la CHB en el paciente con NP |\n|-------------------------------------------|\n| Independientes del soporte nutricional | Dependientes del soporte nutricional |\n|---------------------------------------|---------------------------------------|\n| Enfermedad de base: | Exceso de lípidos |\n| · Sepsis | Exceso de glucosa |\n| · Colelitiasis | Tipo de emulsión lipídica |\n| · Hepatopatía | Ausencia de estímulo enteral |\n| Medicación. | Defecto de nutrientes |\n| Anatomía intestinal: | Infusión continua de NP |\n| · S. bacteriano |\n| · SIC |\n\nS. bacteriano: sobrecrecimiento bacteriano; SIC: síndrome de intestino corto.\n\nFigura 1. Etiología de las Complicaciones Hepatobiliares (CHB).\n\n(mayor probabilidad de colestasis con intesti-\nno delgado remanente menor de 100 cm70);\nademás, se ha observado una mejoría de la\nfunción hepática después de trasplante aisla-\ndo de intestino delgado71.\n\n- La sepsis puede ser la causa de la elevación de\nenzimas hepáticas hasta en el 50% de los pa-\ncientes con NP. La sepsis causa una respuesta\ninflamatoria en el hígado por la liberación de\ncitoquinas proinflamatorias activada por las\nendotoxinas. La liberación de citoquinas pue-\nde alterar la función de la membrana del ca-\nnalículo biliar y reducir el flujo biliar69.\n\n- Sobrecrecimiento bacteriano: El sobrecreci-\nmiento bacteriano es relativamente frecuente\nen pacientes con fallo intestinal por hipomotili-\ndad intestinal con liberación de endotoxinas a\nla circulación portal, las cuales pueden afectar a\nlos hepatocitos72.\n\n• Causas dependientes del tipo de so\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>NUTRICIÓN PARENTERAL<|>EVENT<|>Nutritional support provided intravenously to patients who cannot eat or absorb food through the digestive tract, often associated with complications such as hepatobiliary issues.)\n##\n(\"entity\"<|>HEPATOBILIARY COMPLICATIONS<|>EVENT<|>Complications that arise in the liver and biliary system, often related to prolonged parenteral nutrition, including steatosis and cholestasis.)\n##\n(\"entity\"<|>SEPSIS<|>EVENT<|>A serious medical condition resulting from the body's response to infection, which can lead to elevated liver enzymes in patients receiving parenteral nutrition.)\n##\n(\"entity\"<|>INTESTINAL FAILURE<|>EVENT<|>A condition where the intestines cannot absorb enough nutrients and fluids, often leading to the need for parenteral nutrition.)\n##\n(\"entity\"<|>CITOQUINAS<|>EVENT<|>Inflammatory cytokines released during sepsis that can affect liver function and contribute to hepatobiliary complications.)\n##\n(\"entity\"<|>SOBRECRESCIMIENTO BACTERIANO<|>EVENT<|>A condition characterized by an abnormal increase in bacteria in the intestines, which can occur in patients with intestinal failure and affect liver health.)\n##\n(\"entity\"<|>TRASPLANTE INTESTINAL<|>EVENT<|>A surgical procedure to replace a diseased or damaged intestine, which may improve liver function in patients with hepatobiliary complications.)\n##\n(\"relationship\"<|>NUTRICIÓN PARENTERAL<|>HEPATOBILIARY COMPLICATIONS<|>Nutritional support through parenteral nutrition is associated with various hepatobiliary complications, including steatosis and cholestasis.<|>8)\n##\n(\"relationship\"<|>SEPSIS<|>HEPATOBILIARY COMPLICATIONS<|>Sepsis can lead to elevated liver enzymes and is a significant factor in the development of hepatobiliary complications in patients receiving parenteral nutrition.<|>7)\n##\n(\"relationship\"<|>INTESTINAL FAILURE<|>NUTRICIÓN PARENTERAL<|>Patients with intestinal failure often require parenteral nutrition to meet their nutritional needs.<|>9)\n##\n(\"relationship\"<|>CITOQUINAS<|>HEPATOBILIARY COMPLICATIONS<|>Cytokines released during sepsis can alter liver function and contribute to hepatobiliary complications in patients on parenteral nutrition.<|>6)\n##\n(\"relationship\"<|>SOBRECRESCIMIENTO BACTERIANO<|>HEPATOBILIARY COMPLICATIONS<|>Bacterial overgrowth can occur in patients with intestinal failure and may negatively impact liver health, leading to hepatobiliary complications.<|>5)\n##\n(\"relationship\"<|>TRASPLANTE INTESTINAL<|>HEPATOBILIARY COMPLICATIONS<|>Intestinal transplantation may improve liver function in patients suffering from hepatobiliary complications due to prolonged parenteral nutrition.<|>4)\n<|COMPLETE|>"}]}